Natco Pharma Wins Tentative FDA Nod for Generic Olaparib, Eyes Slice of $2.5B Lynparza Market

US FDA confirms bioequivalence for Natco's generic PARP inhibitor, but commercial launch awaits patent resolution; long-term optionality significant if litigation succeeds.

ndtv-profit-business · 7/20/2026, 6:16:55 AM · Ask about this →